0 Members and 1 Guest are viewing this topic.
in the end, EMAW will always win.
Quote from: DreamWeaver69 on November 04, 2022, 10:32:27 AMI'm just curious how drug addicts get their hookup on the road. You just go to the drug store, what are you talking about?
I'm just curious how drug addicts get their hookup on the road.
you can PM me if you don't wanna say it on main that's fine
Quote from: Sandstone Outcropping on November 03, 2022, 01:42:33 PMQuote from: yoga-like_abana on November 03, 2022, 01:26:32 PMQuote from: Sandstone Outcropping on November 03, 2022, 01:17:49 PMPaper in the New England this week with promising early results for use of psilocybin to treat depression:https://www.nejm.org/doi/full/10.1056/NEJMoa2206443?query=RES&cid=NEJM+Resident+Briefing%2C+November+3%2C+2022+DM1624232_NEJM_Non_Subscriber&bid=1244175369QuoteIn this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.haven't they known all of this for a long time?This is the first time I've seen something published in a high-profile journal like NEJM.I'm interested in micro-dosing to curb the interest in booze. I've been doing some reading on that and also have a pal who does it and is a big believer. He gave me some to try but I never took them.
Quote from: yoga-like_abana on November 03, 2022, 01:26:32 PMQuote from: Sandstone Outcropping on November 03, 2022, 01:17:49 PMPaper in the New England this week with promising early results for use of psilocybin to treat depression:https://www.nejm.org/doi/full/10.1056/NEJMoa2206443?query=RES&cid=NEJM+Resident+Briefing%2C+November+3%2C+2022+DM1624232_NEJM_Non_Subscriber&bid=1244175369QuoteIn this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.haven't they known all of this for a long time?This is the first time I've seen something published in a high-profile journal like NEJM.
Quote from: Sandstone Outcropping on November 03, 2022, 01:17:49 PMPaper in the New England this week with promising early results for use of psilocybin to treat depression:https://www.nejm.org/doi/full/10.1056/NEJMoa2206443?query=RES&cid=NEJM+Resident+Briefing%2C+November+3%2C+2022+DM1624232_NEJM_Non_Subscriber&bid=1244175369QuoteIn this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.haven't they known all of this for a long time?
Paper in the New England this week with promising early results for use of psilocybin to treat depression:https://www.nejm.org/doi/full/10.1056/NEJMoa2206443?query=RES&cid=NEJM+Resident+Briefing%2C+November+3%2C+2022+DM1624232_NEJM_Non_Subscriber&bid=1244175369QuoteIn this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.
In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.
I would legit die. If I have bad panic attacks on weed, I can only imagine what shrooms would do to my dome. My heart would probably burst.
Bad jeans
I guess Wacky isn't invited to our goEMAW mushroom party.
